139 related articles for article (PubMed ID: 38198173)
1. Factors Affecting Treatment Selection Among Patients With Hidradenitis Suppurativa.
Salame N; Sow YN; Siira MR; Garg A; Chen SC; Patzer RE; Kavalieratos D; Orenstein LAV
JAMA Dermatol; 2024 Feb; 160(2):179-186. PubMed ID: 38198173
[TBL] [Abstract][Full Text] [Related]
2. Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.
Lovrić I; Brkić J; Ćorluka M; Čović M; Pejić J; Zeljko Penavić J
Acta Dermatovenerol Croat; 2021 Jul; 29(2):108-110. PubMed ID: 34477078
[TBL] [Abstract][Full Text] [Related]
3. Analysis of Characteristics and Trends in Treatment Response of Hidradenitis Suppurativa Patients: A Southern US Cohort Study.
Peterson GC; Preston A; Frieder J; Wang X; Paek SY
Dermatology; 2020; 236(5):413-420. PubMed ID: 31935718
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal observational study of hidradenitis suppurativa: impact of surgical intervention with adjunctive biologic therapy.
Shanmugam VK; Mulani S; McNish S; Harris S; Buescher T; Amdur R
Int J Dermatol; 2018 Jan; 57(1):62-69. PubMed ID: 29130482
[TBL] [Abstract][Full Text] [Related]
5. The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study.
Rivera-Díaz R; Pozo T; Alfageme F; Díaz Ley B; Osorio GF; Chico R; Vilarrasa E; Silvente C; Ciudad Blanco C; Romaní J; Martorell A; Fernández P; Romero Ferreiro C; Molina Leyva A
Actas Dermosifiliogr; 2023 Oct; 114(9):755-762. PubMed ID: 37331620
[TBL] [Abstract][Full Text] [Related]
6. The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study.
Rivera-Díaz R; Pozo T; Alfageme F; Díaz Ley B; Osorio GF; Chico R; Vilarrasa E; Silvente C; Ciudad Blanco C; Romaní J; Martorell A; Fernández P; Romero Ferreiro C; Molina Leyva A
Actas Dermosifiliogr; 2023 Oct; 114(9):T755-T762. PubMed ID: 37479135
[TBL] [Abstract][Full Text] [Related]
7. Certolizumab pegol in the treatment of severe hidradenitis suppurativa after adalimumab failure: A real-life experience.
Esme P; Akoglu G; Dalkıran CD; Caliskan E
Dermatol Ther; 2022 Nov; 35(11):e15782. PubMed ID: 35996992
[TBL] [Abstract][Full Text] [Related]
8. Pain experiences among those living with hidradenitis suppurativa: a qualitative study.
Orenstein LAV; Salame N; Siira MR; Urbanski M; Flowers NI; Echuri H; Garg A; McKenzie-Brown AM; Curseen KA; Patzer RE; Kavalieratos D; Chen SC
Br J Dermatol; 2023 Jan; 188(1):41-51. PubMed ID: 36689519
[TBL] [Abstract][Full Text] [Related]
9. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.
Kimball AB; Jemec GB; Yang M; Kageleiry A; Signorovitch JE; Okun MM; Gu Y; Wang K; Mulani P; Sundaram M
Br J Dermatol; 2014 Dec; 171(6):1434-42. PubMed ID: 25040429
[TBL] [Abstract][Full Text] [Related]
10. A Novel Severity Assessment Scoring System for Hidradenitis Suppurativa.
Hessam S; Scholl L; Sand M; Schmitz L; Reitenbach S; Bechara FG
JAMA Dermatol; 2018 Mar; 154(3):330-335. PubMed ID: 29417136
[TBL] [Abstract][Full Text] [Related]
11. Demographic Gaps and Requirements for Participation: A Systematic Review of Clinical Trial Designs in Hidradenitis Suppurativa.
James JF; Madray VM; Salame N; Hasan SB; White MS; Barron JR; Kirby J; Ingram JR; Orenstein LAV
Dermatology; 2023; 239(1):45-51. PubMed ID: 36108592
[TBL] [Abstract][Full Text] [Related]
12. Drug Survival of Biologics in Patients With Hidradenitis Suppurativa.
Ring HC; Maul JT; Yao Y; Wu JJ; Thyssen JP; Thomsen SF; Egeberg A
JAMA Dermatol; 2022 Feb; 158(2):184-188. PubMed ID: 34851360
[TBL] [Abstract][Full Text] [Related]
13. Adalimumab Dose Intensification in Recalcitrant Hidradenitis Suppurativa/Acne Inversa.
Zouboulis CC; Hansen H; Caposiena Caro RD; Damiani G; Delorme I; Pascual JC; Reguiai Z; Trigoni A; Vilarrasa E; Alfageme Roldán F
Dermatology; 2020; 236(1):25-30. PubMed ID: 31630144
[TBL] [Abstract][Full Text] [Related]
14. Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials.
Jemec GBE; Okun MM; Forman SB; Gulliver WPF; Prens EP; Mrowietz U; Armstrong AW; Geng Z; Gu Y; Williams DA; Teixeira HD; Kimball AB
Br J Dermatol; 2019 Nov; 181(5):967-975. PubMed ID: 30916379
[TBL] [Abstract][Full Text] [Related]
15. Vascularization and fibrosis are important ultrasonographic tools for assessing response to adalimumab in hidradenitis suppurativa: Prospective study of 32 patients.
Nazzaro G; Calzari P; Passoni E; Vaienti S; Moltrasio C; Barbareschi M; Muratori S; Veraldi S; Marzano AV
Dermatol Ther; 2021 Jan; 34(1):e14706. PubMed ID: 33368976
[TBL] [Abstract][Full Text] [Related]
16. Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa.
Gulliver W; Zouboulis CC; Prens E; Jemec GB; Tzellos T
Rev Endocr Metab Disord; 2016 Sep; 17(3):343-351. PubMed ID: 26831295
[TBL] [Abstract][Full Text] [Related]
17. Combination Therapies for Hidradenitis Suppurativa: A Retrospective Chart Review of 31 Patients.
McPhie ML; Bridgman AC; Kirchhof MG
J Cutan Med Surg; 2019; 23(3):270-276. PubMed ID: 30658534
[TBL] [Abstract][Full Text] [Related]
18. Factors related to the onset and recurrence of flares in hidradenitis suppurativa patients treated with adalimumab.
Caposiena Caro RD; Chiricozzi A; Sechi A; Molinelli E; Venturini M; Candi E; DE Simone C; Peris K; Patrizi A; Offidani A; Calzavara-Pinton P; Bianchi L
Ital J Dermatol Venerol; 2022 Apr; 157(2):137-141. PubMed ID: 33982548
[TBL] [Abstract][Full Text] [Related]
19. Real-world safety and effectiveness of adalimumab in patients with hidradenitis suppurativa: 12-week interim analysis of post-marketing surveillance in Japan.
Hayashi N; Hayama K; Takahashi K; Kurokawa I; Okazaki M; Kashiwagi T; Iwashita E; Terui T
J Dermatol; 2022 Apr; 49(4):411-421. PubMed ID: 35040156
[TBL] [Abstract][Full Text] [Related]
20. Cost-savings of adalimumab in hidradenitis suppurativa: a retrospective analysis of a real-world cohort.
Argyropoulou M; Kanni T; Kyprianou M; Melachroinopoulos N; Giamarellos-Bourboulis EJ
Br J Dermatol; 2019 May; 180(5):1161-1168. PubMed ID: 30192377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
